Latest ARCH VENTURE CORP Stock Portfolio
ARCH VENTURE CORP Performance:
2025 Q1: -16.37%YTD: -16.37%2024: -4.36%
Performance for 2025 Q1 is -16.37%, and YTD is -16.37%, and 2024 is -4.36%.
About ARCH VENTURE CORP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, ARCH Venture Management, LLC reported an equity portfolio of $206.2 Millions as of 31 Mar, 2025.
The top stock holdings of ARCH Venture Management, LLC are BEAM, , . The fund has invested 43% of it's portfolio in BEAM THERAPEUTICS INC. and 22% of portfolio in MAZE THERAPEUTICS, INC.
The fund managers got completely rid off SINGULAR GENOMICS SYSTEMS, INC. (OMIC) and CERO THERAPEUTICS HOLDINGS, INC. (PBAX) stocks. ARCH Venture Management, LLC opened new stock positions in MAZE THERAPEUTICS, INC. and CERO THERAPEUTICS HOLDINGS, INC. (PBAX).
The top stock holdings of ARCH Venture Management, LLC are BEAM, , . The fund has invested 43% of it's portfolio in BEAM THERAPEUTICS INC. and 22% of portfolio in MAZE THERAPEUTICS, INC.
The fund managers got completely rid off SINGULAR GENOMICS SYSTEMS, INC. (OMIC) and CERO THERAPEUTICS HOLDINGS, INC. (PBAX) stocks. ARCH Venture Management, LLC opened new stock positions in MAZE THERAPEUTICS, INC. and CERO THERAPEUTICS HOLDINGS, INC. (PBAX).
ARCH VENTURE CORP Annual Return Estimates Vs S&P 500
Our best estimate is that ARCH Venture Management, LLC made a return of -16.37% in the last quarter. In trailing 12 months, it's portfolio return was -19.57%.
New Buys
| Ticker | $ Bought |
|---|---|
| maze therapeutics, inc. | 45,361,800 |
| cero therapeutics holdings, inc. | 16,134 |
New stocks bought by ARCH VENTURE CORP
Additions
Reductions
Sold off
| Ticker | $ Sold |
|---|---|
| cero therapeutics holdings, inc. | -563,614 |
| singular genomics systems, inc. | -2,460,420 |
ARCH VENTURE CORP got rid off the above stocks
Sector Distribution
ARCH Venture Management, LLC has about 59.5% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 59.5 |
| Others | 40.5 |
Market Cap. Distribution
ARCH Venture Management, LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MID-CAP | 43 |
| UNALLOCATED | 40.5 |
| SMALL-CAP | 11.8 |
| MICRO-CAP | 4.3 |
Stocks belong to which Index?
About 54.8% of the stocks held by ARCH Venture Management, LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 54.8 |
| Others | 45.2 |
ARCH VENTURE CORP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of ARCH VENTURE CORP
ARCH Venture Management, LLC has 9 stocks in it's portfolio. BEAM proved to be the most loss making stock for the portfolio. GOSS was the most profitable stock for ARCH Venture Management, LLC last quarter.
Last Reported on: 15 May, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| BEAM | beam therapeutics inc. | 43.00 | 4,540,130 | 88,668,800 | unchanged | 0.00 | ||
| ERAS | erasca, inc. | 7.34 | 11,055,600 | 15,146,100 | unchanged | 0.00 | ||
| GOSS | gossamer bio, inc. | 4.26 | 8,055,920 | 8,780,950 | unchanged | 0.00 | ||
| OMIC | singular genomics systems, inc. | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| PBAX | cero therapeutics holdings, inc. | 0.01 | 22,102 | 16,134 | new | |||
| PBAX | cero therapeutics holdings, inc. | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| UBX | unity biotechnology, inc. | 0.51 | 1,004,820 | 1,045,010 | unchanged | 0.00 | ||
| VERV | verve therapeutics, inc. | 4.42 | 2,008,810 | 9,119,990 | unchanged | 0.00 | ||
| maze therapeutics, inc. | 22.00 | 4,120,050 | 45,361,800 | new | ||||
| rapport therapeutics, inc. | 18.21 | 3,728,740 | 37,548,400 | unchanged | 0.00 | |||
| q32 bio inc. | 0.26 | 320,482 | 532,000 | unchanged | 0.00 | |||